Loading
Kiora Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Stengone Carmine N., was filed 12 Sept 2024.
Kiora Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Kiora Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 22 October 2025 and 22 October 2026, 3 insiders published 8 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Compared with its exchange (3,171 companies, median 24 filings), a count of 8 filings is below the norm. Our records for Kiora Pharmaceuticals Inc go back to 2016, with 129 purchases and 37 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -10.8 m USD.
Insider buying of Kiora Pharmaceuticals Inc has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
342
Thresholds
n/a
Buy Volume
€13M
129 ops. · all time
Sell Volume
€13M
37 ops. · all time
Since the insiders bought
- -28.7%Entry US$3.66 · Close at T+365 US$2.61
- -27.1%Entry US$3.62 · Close at T+365 US$2.64
- -36.3%Entry US$4.11 · Close at T+365 US$2.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.38
Analyst consensus
1 analystsUS$12.00Target US$12.00(+404%)US$12.00
Income statement
EBITDA-US$12.1M
Net income-US$10.8M0.0% margin
Valuation
P/Book0.9x
Beta-0.22
Balance sheet & cash
Market capUS$10.5M
Total debtUS$368.3k
Free Cash Flow-US$10.1M
Debt / Equity2%
Profitability & ownership
ROE-56.4%
ROA-21.9%
% insiders8.9%
% institutions36.3%
Last declaration on 2 April 2026
Declarations342 total
929 shares@ US$1.9517.3% of flowCommon StockSEC:0001372514-26-000032:0
1,906 shares@ US$1.954.3% of flowCommon StockSEC:0001372514-26-000030:0
929 shares@ US$1.9519.8% of flowCommon StockSEC:0001372514-26-000034:0
6,533 shares0Common StockSEC:0001372514-26-000014:0
16,733 shares0Common StockSEC:0001372514-26-000013:0
6,533 shares0Common StockSEC:0001372514-26-000012:0
238 shares@ US$2.024.6% of flowCommon StockSEC:0001372514-26-000007:0
238 shares@ US$2.020.6% of flowCommon StockSEC:0001372514-26-000006:0
7,772 shares0Common StockSEC:0001372514-25-000036:0
15,941 shares0Common StockSEC:0001372514-25-000034:0
7,772 shares0Common StockSEC:0001372514-25-000035:0
1,250 shares@ US$3.68100.0% of flowCommon StockSEC:0001372514-24-000115:0
Canonical exit: 10 Dec 2024 (T+90)
3,000 shares@ US$3.60100.0% of flowCommon StockSEC:0001372514-24-000113:0
Canonical exit: 9 Dec 2024 (T+90)
1,250 shares@ US$3.86100.0% of flowCommon StockSEC:0001372514-24-000111:0
Canonical exit: 17 Nov 2024 (T+90)
5,000 shares@ US$3.96100.0% of flowCommon StockSEC:0001372514-24-000109:0
Canonical exit: 17 Nov 2024 (T+90)
2,000 shares@ US$3.2174.0% of flowCommon StockSEC:0001372514-24-000107:0
Canonical exit: 12 Nov 2024 (T+90)
15,629 shares0Common StockSEC:0001372514-24-000097:0
7,620 shares0Common StockSEC:0001372514-24-000096:0
7,355 shares0Common StockSEC:0001372514-24-000094:0
100 shares@ US$5.256.2% of flowCommon StockSEC:0001372514-24-000065:0
Canonical exit: 12 Sept 2024 (T+90)
1,431 shares@ US$5.2978.1% of flowCommon StockSEC:0001372514-24-000063:0
Canonical exit: 12 Sept 2024 (T+90)
3,000 shares@ US$4.99918.9% of flowCommon StockSEC:0001372514-24-000060:0
Canonical exit: 11 Sept 2024 (T+90)
5,260 shares@ US$4.88100.0% of flowCommon StockSEC:0001372514-24-000061:0
Canonical exit: 11 Sept 2024 (T+90)
30,000 shares0Common StockSEC:0001372514-23-000150:0
62,500 shares0Common StockSEC:0001372514-23-000149:0
25 of 342 declarations
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker KPRX, and it is the issuer referenced in SEC Form 4 insider-transaction filings. Headquartered in Encinitas, California, United States, Kiora is focused on ophthalmology, with a development strategy centered on innovative therapies for serious retinal diseases. The company was incorporated in Delaware on December 28, 2004, giving it a long operating history in the biotech sector even though it remains a clinical-stage company rather than a commercial-stage pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000047/kprx-20260331.htm?utm_source=openai))
Kiora operates as a single-segment specialty pharmaceutical company focused on ophthalmic products. Its pipeline is currently anchored by two lead programs. KIO-301 is being developed for inherited retinal diseases, especially retinitis pigmentosa, and is designed to target surviving retinal ganglion cells. KIO-104 is an anti-inflammatory candidate aimed at retinal inflammatory conditions, including retinal macular edema. These programs form the core of the company’s investment case. At present, Kiora does not have the diversified commercial portfolio or revenue base of a large-cap drugmaker; instead, it is largely dependent on clinical execution, regulatory progress, and capital access. ([kiorapharma.com](https://kiorapharma.com/technology/kio-301/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Kiora is a niche player in a highly competitive ophthalmology market dominated by larger companies with greater clinical, regulatory, and commercial resources. Its differentiation lies in a focused approach to rare retinal disorders, where unmet medical need remains significant and where successful proof-of-concept data could create partnering or licensing opportunities. That same focus, however, also concentrates risk: the company’s valuation is highly sensitive to trial outcomes, regulatory milestones, and financing conditions. ([ir.kiorapharma.com](https://ir.kiorapharma.com/news-events/news-releases/detail/152/kiora-pharmaceuticals-receives-clinical-trial-approval-for-first-in-human-evaluation-of-kio-301-to-restore-vision-in-patients-with-retinitis-pigmentosa?utm_source=openai))
Recent corporate developments have been important. In March 2026, Kiora reported progress across two active Phase 2 studies, including ABACUS-2 for KIO-301 and KLARITY for KIO-104. In April 2026, the company announced an equity financing involving common stock and warrants, underscoring ongoing capital management in a development-stage model. Its March 31, 2026 quarterly filing stated that, based on cash and short-term investments plus April 2026 financing proceeds, Kiora expected to fund planned operations into late 2028. For investors, this leaves Kiora as a high-risk, high-upside ophthalmic biotech story on the NASDAQ in the United States, with value creation tied primarily to clinical and regulatory success. ([ir.kiorapharma.com](https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000025/ex991-pressreleasedecember.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
